PI3 kinase inhibitors in the clinic: An update

Anticancer Research

Volumn 32, Issue 7, 2012, Pages 2463-2470

  Kurtz, Jean Emmanuel ^a,b,c   Ray Coquard, Isabelle ^b,d  

^a UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^b Groupe des Investigateurs Nationaux Pour le Cancer de l'Ovaire (GINECO)   (France)

^c UNIVERSITÉ DE STRASBOURG   (France)

^d CENTRE LÉON BÉRARD   (France)

Author keywords

Cancer; Inhibitor; PI3K; Review; Targeted therapy

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; ABIRATERONE ACETATE; BAY 806946; BAY 869766; BEVACIZUMAB; BUPARLISIB; CAPECITABINE; CARBOPLATIN; CISPLATIN; ERLOTINIB; EVEROLIMUS; FLUOROPYRIMIDINE; FULVESTRANT; GDC 0068; GDC 0973; GDC 0980; GEFITINIB; GEMCITABINE; IRINOTECAN; MAMMALIAN TARGET OF RAPAMYCIN; OXALIPLATIN; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PICTRELISIB; PROTEIN KINASE B; TEMOZOLOMIDE; TRAMETINIB; TRASTUZUMAB; UNCLASSIFIED DRUG;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; BREAST TUMOR; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CASTRATION RESISTANT PROSTATE CANCER; COLORECTAL CANCER; DRUG BIOAVAILABILITY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; DRUG SYNTHESIS; DRUG TARGETING; DRUG TOLERABILITY; ENDOMETRIUM CARCINOMA; ENZYME ACTIVITY; ENZYME STRUCTURE; GENE MUTATION; GLIOBLASTOMA; HUMAN; KIDNEY CARCINOMA; KIDNEY TUMOR; LUNG NON SMALL CELL CANCER; MOLECULARLY TARGETED THERAPY; NEOPLASM; NONHODGKIN LYMPHOMA; PHARMACODYNAMICS; PRIORITY JOURNAL; REVIEW; SOLID TUMOR;

CLINICAL TRIALS, PHASE II AS TOPIC; HUMANS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN KINASE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84865676740     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (44)

1. Vanhaesebroeck B, Leevers SJ, Panayotou G and Waterfield MD: Phosphoinositide 3-kinases: a conserved family of signal transducers. Trends Biochem Sci 22(7): 267-272, 1997. (Pubitemid 27310948)
2. Wymann MP and Pirola L: Structure and function of phosphoinositide 3-kinases. Biochim Biophys Acta 1436(1-2): 127-150, 1998.
3. Jia S, Roberts TM and Zhao JJ: Should individual PI3 kinase isoforms be targeted in cancer? Curr Opin Cell Biol 21(2): 199-208, 2009.
4. Walker EH, Perisic O, Ried C, Stephens L and Williams RL: Structural insights into phosphoinositide 3-kinase catalysis and signalling. Nature 402 (6759): 313-320, 1999. (Pubitemid 129516270)
5. Mellor P, Furber LA, Nyarko JN and Anderson DH: Multiple roles for the p85alpha isoform in the regulation and function of PI3K signalling and receptor trafficking. Biochem J 441(1): 23-37, 2012.
6. Gabelli SB, Huang CH, Mandelker D, Schmidt-Kittler O, Vogelstein B and Amzel LM: Structural effects of oncogenic PI3Kalpha mutations. Curr Top Microbiol Immunol 347: 43-53, 2010.
7. Samuels Y and Waldman T: Oncogenic mutations of PIK3CA in human cancers. Cell Cycle 3 (10): 1221-1224, 2012.
8. Kang S, Denley A, Vanhaesebroeck B and Vogt PK: Oncogenic transformation induced by the p110beta, -gamma, and -delta isoforms of class I phosphoinositide 3-kinase. Proc Natl Acad Sci USA 103(5): 1289-1294, 2006. (Pubitemid 43191158)
9. Castellano E and Downward J: RAS Interaction with PI3K: More Than Just Another Effector Pathway. Genes Cancer 2(3): 261-274, 2011.
10. Cantley LC: The phosphoinositide 3-kinase pathway. Science 296(5573): 1655-1657, 2002.
11. Jung KH, Choi MJ, Hong S, Lee H, Hong SW, Zheng HM, Lee HS and Hong SS: HS-116, a novel phosphatidylinositol 3-kinase inhibitor induces apoptosis and suppresses angiogenesis of hepatocellular carcinoma through inhibition of the PI3K/AKT/mTOR pathway. Cancer Lett 316(2): 187-195, 2012.
12. Hollander MC, Blumenthal GM and Dennis PA: PTEN loss in the continuum of common cancers, rare syndromes and mouse models. Nat Rev Cancer 11(4): 289-301, 2011.
13. Sarbassov DD, Guertin DA, Ali SM and Sabatini DM: Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307(5712): 1098-1101, 2005. (Pubitemid 40262113)
14. Maira SM, Pecchi S, Huang A, Burger M, Knapp M, Sterker D, Schnell C, Guthy D, Nagel T, Wiesmann M, Brachmann S, Fritsch C, Dorsch M, Chene P, Shoemaker K, De Pover A, Menezes D, Martiny-Baron G, Fabbro D, Wilson CJ, Schlegel R, Hofmann F, Garcia-Echeverria C, Sellers WR and Voliva CF: Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor. Mol Cancer Ther 11(2): 317-328, 2012.
15. Oda K, Stokoe D, Taketani Y and McCormick F: High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma. Cancer Res 65(23): 10669-10673, 2005. (Pubitemid 41713332)
16. Zhao L and Vogt PK: Helical domain and kinase domain mutations in p110alpha of phosphatidylinositol 3-kinase induce gain of function by different mechanisms. Proc Natl Acad Sci USA 105(7): 2652-2657, 2008. (Pubitemid 351520568)
17. Zhao L and Vogt PK: Class I PI3K in oncogenic cellular transformation. Oncogene 27(41): 5486-5496, 2008.
18. Huang CH, Mandelker D, Schmidt-Kittler O, Samuels Y, Velculescu VE, Kinzler KW, Vogelstein B, Gabelli SB and Amzel LM: The structure of a human p110alpha/p85alpha complex elucidates the effects of oncogenic PI3Kalpha mutations. Science 318(5857): 1744-1748, 2007. (Pubitemid 350274378)
19. Gabelli SB, Duong-Ly KC, Brower ET and Amzel LM: Capitalizing on tumor genotyping: towards the design of mutation specific inhibitors of phosphoinsitide-3-kinase. Adv Enzyme Regul 51(1): 273-279, 2011.
20. Powis G, Bonjouklian R, Berggren MM, Gallegos A, Abraham R, Ashendel C, Zalkow L, Matter WF, Dodge J, Grindey G et al: Wortmannin, a potent and selective inhibitor of phosphatidyli-nositol-3-kinase. Cancer Res 54(9): 2419-2423, 1994.
21. Vlahos CJ, Matter WF, Hui KY and Brown RF: A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). J Biol Chem 269(7): 5241-5248, 1994.
22. Maira SM, Stauffer F, Brueggen J, Furet P, Schnell C, Fritsch C, Brachmann S, Chene P, De Pover A, Schoemaker K, Fabbro D, Gabriel D, Simonen M, Murphy L, Finan P, Sellers W and Garcia-Echeverria C: Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol Cancer Ther 7 (7): 1851-1863, 2008.
23. Serra V, Markman B, Scaltriti M, Eichhorn PJ, Valero V, Guzman M, Botero ML, Llonch E, Atzori F, Di Cosimo S, Maira M, Garcia-Echeverria C, Parra JL, Arribas J and Baselga J: NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Res 68(19): 8022-8030, 2008.
24. Brachmann SM, Hofmann I, Schnell C, Fritsch C, Wee S, Lane H, Wang S, Garcia-Echeverria C and Maira SM: Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells. Proc Natl Acad Sci USA 106(52): 22299-22304, 2009.
25. Burris HA, Rodon J, Sharma S, Herbst R, Tabernero J, Infante R, Silva A, Demanse D, Hackl W and Baselga J: First-in-human phase I study of the oral PI3K inhibitor BEZ235 in patients (pts) with advanced solid tumors. J Clin Oncol 28(15s), 2010.
26. Peyton J, Rodon J, Ahnert H, Burris HA, Britten C, Chen LC, Tabernero J, Duval V, Rouyrre N, Silva A, Quadt C and Baselga J: A dose-escalation study with the novel formulation of the oral pan-class I PI3K inhibitor BEZ235, solid dispersion system (SDS) sachet, in patients with advanced solid tumors. J Clin Oncol 29s, 2011.
27. Oda K, Shoji K, Nakagawa S, Kayishima T, Ikeda Y, Miyamoto Y, Tanikawa M, Kuramoto H, Nishida M, Hiraike-Wada O, Yano T, Kozuma S and Taketani Y: Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas. J Clin Oncol 29s, 2011.
28. Zheng Y, Yang J, Qian J, Zhang L, Lu Y, Li H, Lin H, Lan Y, Liu Z, He J, Hong S, Thomas S, Shah J, Baladandayuthapani V, Kwak LW and Yi Q: Novel phosphatidylinositol 3-kinase inhibitor NVP-BKM120 induces apoptosis in myeloma cells and shows synergistic anti-myeloma activity with dexamethasone. J Mol Med (Berl), 2011.
29. Koul D, Fu J, Shen R, LaFortune TA, Wang S, Tiao N, Kim YW, Liu JL, Ramnarian D, Yuan Y, Garcia-Echevrria C, Maira SM and Yung WK: Antitumor activity of NVP-BKM120 - a selective pan class I PI3 kinase inhibitor showed differential forms of cell death based on p53 status of glioma cells. Clin Cancer Res 18(1): 184-195, 2012.
30. Tredan O, Pissaloux D, Treilleux I, Wanq Q, Bonichon-Lamichhane V, Mari V, Freyer G, Pujade-Lauraine E and Ray-Coquard I: Immunohistochemistry and molecular biology of the PI3K pathway did not correlate with treatment efficacy of everolimus as second line or third line treatment of advanced endometrial carcinoma. Eur J Cancer 47(32s), 2010.
31. Park E, Park J, Han SW, Im SA, Kim TY, Oh DY and Bang YJ: NVP-BKM120, a novel PI3K inhibitor, shows synergism with a STAT3 inhibitor in human gastric cancer cells harboring KRAS mutations. Int J Oncol 40(4): 1259-1266, 2012.
32. Bendell JC, Rodon J, Burris HA, de Jonge M, Verweij J, Birle D, Demanse D, De Buck SS, Ru QC, Peters M, Goldbrunner M and Baselga J: Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors. J Clin Oncol 30(3): 282-290, 2012.
33. Patnaik A, Appleman L, Mountz J, Ramanathan R, Beeram M, Tolcher A, Papadopoulos K, Lotze M, Petro D, Laymon C, Paige L, Rajagopalan P, Jeffers M, Roth D and Dubowy R: A first-inhuman phase I study of intravnous PI3K inhibitor BAY 80-6946 in patients with advanced solid tumors: Results of doseescalation phase. J Clin Oncol 29s, 2011.
34. Raynaud FI, Eccles SA, Patel S, Alix S, Box G, Chuckowree I, Folkes A, Gowan S, De Haven Brandon A, Di Stefano F, Hayes A, Henley AT, Lensun L, Pergl-Wilson G, Robson A, Saghir N, Zhyvoloup A, McDonald E, Sheldrake P, Shuttleworth S, Valenti M, Wan NC, Clarke PA and Workman P: Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941. Mol Cancer Ther 8(7): 1725-1738, 2009.
35. Folkes AJ, Ahmadi K, Alderton WK, Alix S, Baker SJ, Box G, Chuckowree IS, Clarke PA, Depledge P, Eccles SA, Friedman LS, Hayes A, Hancox TC, Kugendradas A, Lensun L, Moore P, Olivero AG, Pang J, Patel S, Pergl-Wilson GH, Raynaud FI, Robson A, Saghir N, Salphati L, Sohal S, Ultsch MH, Valenti M, Wallweber HJ, Wan NC, Wiesmann C, Workman P, Zhyvoloup A, Zvelebil MJ and Shuttleworth SJ: The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl) -4- morpholin-4-yl-t hieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer. J Med Chem 51(18): 5522-5532, 2008.
36. Burrows N, Babur M, Resch J, Ridsdale S, Mejin M, Rowling EJ, Brabant G and Williams KJ: GDC-0941 inhibits metastatic characteristics of thyroid carcinomas by targeting both the phosphoinositide-3 kinase (PI3K) and hypoxia-inducible factor-1alpha (HIF-1alpha) pathways. J Clin Endocrinol Metab 96(12): E1934-1943, 2011.
37. Hoeflich KP, Merchant M, Orr C, Chan J, Den Otter D, Berry L, Kasman I, Koeppen H, Rice K, Yang NY, Engst S, Johnston S, Friedman LS and Belvin M: Intermittent administration of MEK inhibitor GDC-0973 plus PI3K inhibitor GDC-0941 triggers robust apoptosis and tumor growth inhibition. Cancer Res 72 (1): 210-219, 2012.
38. Zou ZQ, Zhang LN, Wang F, Bellenger J, Shen YZ and Zhang XH: The novel dual PI3K/mTOR inhibitor GDC-0941 synergizes with the MEK inhibitor U0126 in non-small cell lung cancer cells. Mol Med Report 5(2): 503-508, 2012.
39. Sarker D, Kristeleit R, Mazina K, Ware JA, Yan Y, Dresser M, Derynck M and De Bono J: A phase I study evaluating the pharmacokinetics (PK) and pharmacodynamics (PD) of the oral pan-phosphoinositide-3 kinase (PI3K) inhibitor GDC-0941. J Clin Oncol 27(15s), 2009.
40. Moreno Garcia V, Baird R, Shah K, Basu B, Tunariu N, Blanco M, Cassier P, Pedersen J, Puglisi M, Sarker D, Papadatos-Pastos D, Omlin A, Biondo A, Ware JA, Koeppen H, Levy G, Mazina K and De Bono J: A phase I study evaluating GDC-0941, an oral phosphoinositide-3 kinase (PI3K) inhibitor, in patients with advanced solid tumors or multiple myeloma. J Clin Oncol 29s, 2011.
41. Wallin JJ, Edgar KA, Guan J, Berry M, Prior WW, Lee L, Lesnick JD, Lewis C, Nonomiya J, Pang J, Salphati L, Olivero AG, Sutherlin DP, O'Brien C, Spoerke JM, Patel S, Lensun L, Kassees R, Ross L, Lackner MR, Sampath D, Belvin M and Friedman LS: GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway. Mol Cancer Ther 10(12): 2426-2436, 2011.
42. Sutherlin DP, Bao L, Berry M, Castanedo G, Chuckowree I, Dotson J, Folks A, Friedman L, Goldsmith R, Gunzner J, Heffron T, Lesnick J, Lewis C, Mathieu S, Murray J, Nonomiya J, Pang J, Pegg N, Prior WW, Rouge L, Salphati L, Sampath D, Tian Q, Tsui V, Wan NC, Wang S, Wei B, Wiesmann C, Wu P, Zhu BY and Olivero A: Discovery of a potent, selective, and orally available class I phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) kinase inhibitor (GDC-0980) for the treatment of cancer. J Med Chem 54(21): 7579-7587, 2011.
43. Wagner A, Bendell JC, Dolly S, Morgan J, Ware JA, Fredrickson J, Mazina K, Lauchle J, Burris HA and De Bono J: A first-inhuman phase I study to evaluate GDC-0980, an oral PI3K/mTOR inhibitor, administered QD in patients with advanced solid tumors. J Clin Oncol 29s, 2011.
44. Dolly S, Wagner A, Bendell JC, Yan Y, Ware JA, Mazina K, Holden S, Derynck M, De Bono J and Burris HA: A first-in-human, phase I study to evaluate the dual PI3K/mTOR inhibitor GDC-0980 administered QD in patients with advanced solid tumors or non-Hodgkin's lymphoma. J Clin Oncol 28(15s), 2010.